Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | SBI Healthcare Opportunities Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹96.39 |
| 26 Aug 2009 | ₹80.31 |
| 08 May 2011 | ₹119.63 |
| 17 Jan 2013 | ₹162.06 |
| 30 Sep 2014 | ₹303.51 |
| 11 Jun 2016 | ₹329.50 |
| 21 Feb 2018 | ₹301.23 |
| 04 Nov 2019 | ₹242.04 |
| 16 Jul 2021 | ₹489.64 |
| 28 Mar 2023 | ₹441.53 |
| 08 Dec 2024 | ₹891.38 |
| 20 Aug 2026 | ₹1070.53 |
| Metric | SBI · Regular · IDCW NAV ₹326.19 Very High risk ★★★★★ | Category median Sectoral/ Thematic · 248 funds |
|---|---|---|
| +18.89% | +3.54% | |
| +23.23% | +11.47% | |
| +18.11% | +9.70% | |
| +11.91% | +10.32% | |
| +12.34% | +9.15% | |
| +22.66% | — | |
| +15.06% | +12.10% | |
| +14.40% | +10.32% | |
| +12.26% | +8.80% | |
| Risk | ||
| 12.82% | 15.91% | |
| 1.30 | 0.25 | |
| 1.85 | 0.32 | |
| -63.31% | -26.14% | |
| Nifty 500 | — | |
| +11.81% | -0.04% | |
| 0.64 | 0.98 | |
| 109.0% | 98.3% | |
| 49.0% | 101.5% | |
| 2.00% | 2.38% | |
| ₹4,319Cr | ₹1,160Cr | |
| 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 35% | 42% | |
| Tanmay Desai | — | |
| 03 Apr 2006 | — | |
| 31 | — | |
| 52.2% | — | |
| 2.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.